Inhibitor Therapeutics, Inc. (INTI) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
4830 W. KENNEDY BLVD. TAMPA, FL 33609 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 6/30/2025 MRQ | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 5,607 | 8,840 | 11,951 | 31 | 75 | 804 | |||
| Cash and cash equivalent | 5,607 | 8,840 | 11,951 | 31 | 75 | 804 | |||
| Prepaid expense | 24 | 28 | 32 | 42 | |||||
| Other undisclosed current assets | 88 | 109 | |||||||
| Total current assets: | 5,695 | 8,949 | 11,975 | 59 | 107 | 846 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | |||||||||
| Other noncurrent assets | 24 | 54 | |||||||
| Total noncurrent assets: | 24 | 54 | |||||||
| TOTAL ASSETS: | 5,695 | 8,949 | 11,975 | 59 | 132 | 900 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 710 | 665 | 268 | 396 | 370 | 417 | |||
| Interest and dividends payable | ✕ | ✕ | ✕ | ✕ | 116 | 101 | 101 | ||
| Accounts payable | 16 | 34 | 145 | 280 | 269 | 316 | |||
| Accrued liabilities | 694 | 631 | 123 | ||||||
| Debt | 30 | ||||||||
| Other liabilities | 53 | 25 | 14 | ||||||
| Due to related parties | ✕ | ✕ | ✕ | 411 | 231 | ||||
| Total current liabilities: | 710 | 665 | 679 | 680 | 425 | 431 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 12 | ||||||||
| Long-term debt, excluding current maturities | 12 | ||||||||
| Other undisclosed long-term debt and lease obligation | |||||||||
| Liabilities, other than long-term debt | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | |||
| Deferred revenue | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | 3,000 | |||
| Other undisclosed noncurrent liabilities | 55 | ||||||||
| Total noncurrent liabilities: | 3,000 | 3,000 | 3,000 | 3,000 | 3,067 | 3,000 | |||
| Total liabilities: | 3,710 | 3,665 | 3,679 | 3,680 | 3,492 | 3,431 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 1,985 | 5,284 | 8,296 | (3,621) | (3,360) | (2,531) | |||
| Common stock | 17 | 17 | 17 | 38 | 37 | 37 | |||
| Additional paid in capital | 54,087 | 54,047 | 54,033 | 50,052 | 49,814 | 49,385 | |||
| Accumulated deficit | (52,119) | (48,780) | (45,754) | (57,671) | (57,172) | (55,914) | |||
| Other undisclosed equity, attributable to parent | 3,961 | 3,961 | 3,961 | ||||||
| Total equity: | 1,985 | 5,284 | 8,296 | (3,621) | (3,360) | (2,531) | |||
| TOTAL LIABILITIES AND EQUITY: | 5,695 | 8,949 | 11,975 | 59 | 132 | 900 | |||
Income Statement (P&L) ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues (gain on Disposition of Assets for Financial Service Operations) | 42 | |||||||
| Gross profit: | 42 | |||||||
| Operating expenses | (3,657) | (3,405) | (658) | (325) | (1,059) | (2,748) | ||
| Other undisclosed operating loss | (42) | |||||||
| Operating loss: | (3,657) | (3,405) | (658) | (325) | (1,059) | (2,748) | ||
| Interest and debt expense | (23) | |||||||
| Loss from continuing operations before equity method investments, income taxes: | (3,657) | (3,405) | (681) | (325) | (1,059) | (2,748) | ||
| Other undisclosed income from continuing operations before income taxes | 379 | 12,842 | ||||||
| Income (loss) from continuing operations before income taxes: | (3,657) | (3,026) | 12,161 | (325) | (1,059) | (2,748) | ||
| Income tax expense | (55) | |||||||
| Income (loss) from continuing operations: | (3,657) | (3,026) | 12,106 | (325) | (1,059) | (2,748) | ||
| Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (325) | (1,059) | (2,748) | |
| Other undisclosed net income | 27 | 1 | 15 | |||||
| Net income (loss): | (3,657) | (3,026) | 12,106 | (299) | (1,058) | (2,733) | ||
| Other undisclosed net income attributable to parent | 318 | |||||||
| Net income (loss) attributable to parent: | (3,339) | (3,026) | 12,106 | (299) | (1,058) | (2,733) | ||
| Preferred stock dividends and other adjustments | (189) | |||||||
| Net income (loss) available to common stockholders, diluted: | (3,339) | (3,026) | 11,917 | (299) | (1,058) | (2,733) | ||
Comprehensive Income ($ in thousands)
| 6/30/2025 TTM | 12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (3,657) | (3,026) | 12,106 | (299) | (1,058) | (2,733) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (3,657) | (3,026) | 12,106 | (299) | (1,058) | (2,733) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.